期刊文献+

艾塞那肽合成

Synthesis of exenatide
下载PDF
导出
摘要 目的:开发一种高效率、低成本合成艾塞那肽的方法以满足规模化生产需要。方法:以N-C延伸策略,将艾塞那肽的39个氨基酸分成13个小片段,先用液相法分别合成12个N端Fmoc保护小片段肽,用固相法合成第13个肽树脂片段,然后用固相法将12个小片段依次连接到第13个肽树脂片段上,得到艾塞那肽树脂,切割后得到艾塞那肽粗品。最后经反相色谱纯化、冷冻干燥等过程,得到艾塞那肽。结果:合成的艾塞那肽质谱表征结构正确,液相色谱显示纯度大于98%。结论:本方法提高了合成效率,减少杂质累积,降低了纯化难度,适合规模化生产。 Objective: To develop a high efficacy and cost-effective method for the synthesis of exenatide to meet the requirement of a scale production. Methods: Thirty-nine amino acids in exenatide were divided into 13 small protected peptide fragments based on N-C extension strategy, the first to 12 th fragments were synthesized by a liquid-phase method, respectively while the 13 th fragment was synthesized by a solid-phase method and then the first to 12 th fragments were in turn connected into. Fmoc-protective fragment to obtain exenatide resin, which was cleavaged to obtain crude exenatide. Finally, exenatide was obtained by reverse phase HPLC purification and lyophilization. Results: The structure of the synthesized exenatide was verified to be correct by mass spectrometry characterization and its purity was 98% by HPLC. Conclusion: The synthesis efficiency can be improved and the accumulation of impurities and the difficulty of purification can be reduced by this method, which is suitable for the large-scale production of exenatide.
作者 王慧 张忠旗 杨小琳 赵金礼 WANG Hui;ZHANG Zhongqi;YANG Xiaolin;ZHAO Jinli(Shaanxi Huikang Bio Tech Co.,Ltd.,Xi'an 710054,China)
出处 《上海医药》 CAS 2018年第11期84-88,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 艾塞那肽 片段肽 多肽合成 exenatide peptide fragments peptide synthesis
  • 相关文献

参考文献2

二级参考文献20

  • 1韩香,王德心.多肽合成中“困难序列”的缩合研究进展(英文)[J].药学学报,2007,42(2):111-117. 被引量:12
  • 2Murphy C E. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus [ J ]. Ann Pharmacother, 2012,46 : 812 - 821.
  • 3Norris S L, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review [ J ]. Diabet Med,2009,26 : 837 - 846.
  • 4Mikhail N. Exenatide : a novel approach for treatment of type 2 diabetes [ J ]. South Med J,2006,99 : 1271 - 1279.
  • 5Yoo B K, Triller D M, Yoo D J. Exenatide : a new option for the treatment of type 2 diabetes [ J ]. Ann Pharmacother, 2006,40 : 1777 - 1784.
  • 6Giannoukakis N. Exenatide. Amylin/Eli Lilly[ J J. Curt Opin in Investig Drugs,2003,4:459 - 465.
  • 7Walczak I M. Lilly and Amylin to collaborate on potential breakthrough diabetes treatment. [ J ]. Diabetes Technol Ther, 2002,4:738 -739.
  • 8Pasquale P, Dmitry A S. New TFA-Free cleavage and final deprotection in Fmoc Solid-Phase peptide synthesis : dilute HC1 in fluoroalcohol [ J ]. Org Lett,2012,14:6346 - 6349.
  • 9Blonde L,Klein E,Han J. Interim analysis of the effects of exenatide treatment on A1C,weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes[J].Diabetes,Obesity and Metabolism,2006,(04):436-447.
  • 10Best JH,Hoogwerf BJ,Herman WH. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies:a retrospective analysis of the LifeLink database[J].Diabetes Care,2011,(01):90-95.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部